Intuitive Surgical TodayISRGIntuitive Surgical$502.35 -8.65 (-1.69%) 52-Week Range$425.00▼$616.00P/E Ratio73.82Price Target$593.09Add to WatchlistThe world’s second-largest company in the healthcare equipment and supplies industry, Intuitive Surgical NASDAQ: ISRG, just reported Q2 financials. The results were solid, but not enough to move shares higher. After dipping nearly 4% after-hours on July 22, Intuitive Surgical shares were essentially flat by 8PM EST, possibly reflecting conservative tone in future ...

Intuitive Surgical (ISRG) Q2 2025 Earnings Call July 22, 2025 04:30 PM ET Company ParticipantsDan Connally - VP & Head - Investor RelationsDavid Rosa - CEO & DirectorJamie Samath - CFO & Enterprise Technology LeaderTravis Steed - MD - Equity ResearchDavid Roman - Managing DirectorRick Wise - Managing DirectorConference Call ParticipantsRobert Marcus - Senior AnalystLawrence Biegelsen - Senior Medical Device Equity Research AnalystAdam Maeder - MD & Senior Research AnalystOperatorHello, everyone, and welcome ...

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 MedRobot 2025年5月15日，直觉医疗（Intuitive，纳斯达克代码：ISRG）宣布，现任公司总裁 Dave Rosa 将于 2025年7月1日 正式接任 首席执行官 。现任CEO Gary Guthart 将转任公司 董事会执行主席 ，继续参 与战略指导与过渡安排。 此次调整被明确为公司长期继任计划的一部分，董事会表示，Rosa在公司战略制定、产品体系发展及全 球布局方面发挥了关键作用，是"推动公司下一阶段增长的合适人选"。 # 从7200万美元到83亿美元，一位掌舵者的二十年 在他的带领下，直觉医疗完成了产品、市场和模式三大扩展： 推动达芬奇系统从泌尿科拓展至普外、妇科和结直肠等多个术式； 在全球超过70个国家建立销售与服务网络，系统安装量破万台； 形成以设备、耗材与服务为一体的生态闭环，2024年实现营收 83.5亿美元。 截至目前， 累 计手术量 超过 1 ...

Core Viewpoint - Intuitive Surgical (ISRG) has shown a recovery in its stock price after a significant decline, driven by strong fundamentals and a favorable trade environment despite ongoing tariff risks [1][2]. Financial Performance and Revenue Growth - ISRG reported first-quarter 2025 revenues of $2.25 billion, reflecting a 19.2% year-over-year increase, with 85% of total earnings coming from consistent, recurring revenues [3]. - The company achieved a 20% growth in earnings per share (EPS), reaching $1.81, and maintained an operating margin of 34.1%, although a decline in operating margin is anticipated for 2025 due to increased depreciation and a higher mix of lower-margin products [3]. Market Performance - Despite a recent drop in share price, ISRG's shares have increased by 8.4%, outperforming the Zacks Medical - Instruments industry's decline of 6.9% year to date [4]. Procedure Volume and Market Expansion - Revenue growth in the first quarter was driven by increased da Vinci procedure volume and strong growth in Ion and SP procedures, with the company raising procedure prices to combat inflation [7]. - The adoption of the da Vinci 5 system is expected to boost revenues, with plans for a broad launch in the second half of the year, although challenges in markets like Germany, the U.K., and Japan may slow adoption [8]. - Recent FDA clearance for the da Vinci Single Port surgical system is anticipated to further enhance system revenues [9]. Competitive Challenges and Market Headwinds - ISRG expects a gross margin headwind of 170 basis points in 2025 due to global tariffs, particularly from U.S.-China trade tensions and European retaliatory tariffs [10]. - The company faces increasing competition in robotic-assisted surgery from major players like Johnson & Johnson and Medtronic, which are investing heavily in this space [12]. Valuation and Investment Outlook - ISRG's stock is trading at a premium compared to the industry, raising concerns about valuation, although it is below its five-year median [16]. - The company holds a Zacks Rank 3 (Hold), with Style Scores indicating a Value Score of D and a Growth Score of C, suggesting caution for new positions while indicating potential upside based on strong fundamentals [17][18].

Financial Data and Key Metrics Changes - First quarter revenue was $2.25 billion, a 19% increase year over year, with constant currency growth at 20% [29][30] - Pro forma gross margin for Q1 was 66.4%, down from 67.6% in the same quarter last year, primarily due to higher facility costs and a mix of newer products [34] - Pro forma net income for Q1 was $662 million, or $1.81 per share, compared to $541 million, or $1.50 per share, in the prior year [37] Business Line Data and Key Metrics Changes - Da Vinci procedure growth was 17% in Q1, with significant strength in general surgery in the US and notable performance in India and Korea [9][26] - Capital placements included 367 da Vinci systems, a 17% increase from the previous year, with 147 being da Vinci V systems [10][27] - ION procedures grew 58% to approximately 31,000 in the quarter, with 49 ION systems placed [32] Market Data and Key Metrics Changes - US procedures grew 13%, driven by benign general surgery, while OUS procedures grew 24%, led by India and Korea [26][78] - Procedure growth in China improved from the prior quarter, primarily driven by urologic procedures [26] - The installed base of da Vinci systems grew 15% year over year [25] Company Strategy and Development Direction - The company aims to assure product supply globally and optimize production costs amid dynamic trade policies [7][8] - Focus on the full launch of da Vinci V and increasing adoption of focused procedures through training and market access efforts [19][20] - Commitment to building industrial scale, product quality, and manufacturing optimization [19] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in procedure growth, raising the full-year 2025 procedure growth forecast to 15% to 17% [39] - The impact of tariffs is expected to add approximately 1.7% to cost of sales, with a potential increase in impact as the year progresses [24][41] - Management remains cautious about the capital environment, noting potential constraints in key OUS markets due to government budget limitations [48][80] Other Important Information - The company opened new manufacturing facilities in California to expand its US manufacturing and R&D footprint [35] - The average selling price for da Vinci systems increased to $1.62 million, driven by a higher mix of da Vinci V placements [31] - The company is focused on enhancing its digital tools and computational capabilities to support surgical performance [17] Q&A Session Summary Question: Impact of tariffs on financials - Management indicated that approximately half of the tariff impact is related to US-China trade, with the remainder from imports into the US from other countries [45] Question: Capital environment and customer response - Management noted strong customer response to da Vinci V in the US, with leasing arrangements providing flexibility amid capital constraints [48] Question: OUS growth drivers - Management highlighted strong growth in early-stage markets like India and Taiwan, with ongoing efforts to engage key opinion leaders and surgical societies [80]